Published in PLoS Pathog on May 02, 2008
Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol (2008) 5.17
Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med (2011) 1.14
HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol (2015) 1.06
Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One (2012) 1.01
Timing of immune escape linked to success or failure of vaccination. PLoS One (2010) 1.00
High-avidity, high-IFNγ-producing CD8 T-cell responses following immune selection during HIV-1 infection. Immunol Cell Biol (2011) 0.96
Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques. J Virol (2009) 0.96
Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine (2010) 0.91
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology (2012) 0.90
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med (2010) 0.89
Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques. J Virol (2012) 0.81
Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine (2014) 0.81
Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia. Curr Opin HIV AIDS (2010) 0.81
An "escape clock" for estimating the turnover of SIV DNA in resting CD4⁺ T cells. PLoS Pathog (2012) 0.80
Inactivated simian immunodeficiency virus-pulsed autologous fresh blood cells as an immunotherapy strategy. J Virol (2008) 0.79
Broadening of the T-cell repertoire to HIV-1 Gag p24 by vaccination of HLA-A2/DR transgenic mice with overlapping peptides in the CAF05 adjuvant. PLoS One (2013) 0.78
Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in simian immunodeficiency virus infection. J Virol (2014) 0.78
In-vivo stimulation of macaque natural killer T cells with α-galactosylceramide. Clin Exp Immunol (2013) 0.77
Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. PLoS One (2014) 0.76
SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques. Retrovirology (2011) 0.76
Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals. PLoS One (2013) 0.75
A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals. PLoS One (2013) 0.75
Analysis of serial measurements in medical research. BMJ (1990) 16.69
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09
Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature (2005) 13.15
CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med (2006) 10.34
Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med (1996) 7.06
Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol (2005) 5.76
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14
Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication. J Virol (2007) 3.85
Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med (2002) 2.76
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med (2000) 2.33
Limited durability of viral control following treated acute HIV infection. PLoS Med (2004) 2.16
Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J Virol (2002) 2.13
Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 1.63
Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J Virol (2005) 1.52
Control of SIV rebound through structured treatment interruptions during early infection. Science (2000) 1.48
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol (2007) 1.22
MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics (2006) 1.21
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses (2006) 1.21
Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol (2007) 1.17
The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol (2005) 1.15
Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol (2006) 1.15
Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology (2002) 1.12
Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol (2006) 1.03
Enhanced cellular immunity in macaques following a novel peptide immunotherapy. J Virol (2005) 1.02
Control of viral rebound through therapeutic immunization with DermaVir. AIDS (2005) 0.99
Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine (2005) 0.99
Induction of T-cell immunity to antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol (2005) 0.99
DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued. Virology (2006) 0.96
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med (2006) 9.21
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet (2006) 4.45
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr (2005) 3.18
Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J Virol (2005) 3.03
Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin Infect Dis (2009) 2.89
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. Proc Natl Acad Sci U S A (2012) 2.64
HIV-1 drug resistance mutations among antiretroviral-naive HIV-1-infected patients in Asia: results from the TREAT Asia Studies to Evaluate Resistance-Monitoring Study. Clin Infect Dis (2011) 2.08
Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis (2012) 2.01
Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS (2002) 1.98
Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol (2013) 1.95
Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol (2008) 1.83
Preexisting CD8+ T-cell immunity to the H7N9 influenza A virus varies across ethnicities. Proc Natl Acad Sci U S A (2014) 1.83
The impact of behavioural changes on the prevalence of human immunodeficiency virus and hepatitis C among injecting drug users. Int J Epidemiol (2003) 1.78
Importance of promoting HIV testing for preventing secondary transmissions: modelling the Australian HIV epidemic among men who have sex with men. Sex Health (2009) 1.70
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS (2014) 1.59
Immune escape from HIV-specific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A (2011) 1.58
Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol (2009) 1.57
Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol (2013) 1.53
Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes. J Virol (2005) 1.52
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS (2007) 1.49
Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. J Hepatol (2006) 1.45
Injecting drug use in Australia: needle/syringe programs prove their worth, but hepatitis C still on the increase. Med J Aust (2003) 1.41
Vaccination and timing influence SIV immune escape viral dynamics in vivo. PLoS Pathog (2008) 1.34
A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS (2006) 1.33
The utility of ADCC responses in HIV infection. Curr HIV Res (2008) 1.30
Suicide risk among recently released prisoners in New South Wales, Australia. Med J Aust (2007) 1.28
Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr (2011) 1.24
Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol (2005) 1.23
An enormous hepatitis B virus-related liver disease burden projected in Vietnam by 2025. Liver Int (2008) 1.23
Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS (2010) 1.23
High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J Immunol (2009) 1.22
MHC class I allele frequencies in pigtail macaques of diverse origin. Immunogenetics (2006) 1.21
Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J Virol (2013) 1.21
Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity. Trends Microbiol (2005) 1.21
Comparative evaluation of simian, simian-human, and human immunodeficiency virus infections in the pigtail macaque (Macaca nemestrina) model. AIDS Res Hum Retroviruses (2006) 1.21
Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology (2013) 1.19
Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection. J Virol (2011) 1.19
Vaccine-induced T cells control reversion of AIDS virus immune escape mutants. J Virol (2007) 1.19
Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol (2007) 1.18
AIDS-related and non-AIDS-related mortality in the Asia-Pacific region in the era of combination antiretroviral treatment. AIDS (2009) 1.17
Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr (2009) 1.16
The pigtail macaque MHC class I allele Mane-A*10 presents an immundominant SIV Gag epitope: identification, tetramer development and implications of immune escape and reversion. J Med Primatol (2005) 1.15
Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol (2006) 1.15
Predictors of hypertension and changes of blood pressure in HIV-infected patients. Antivir Ther (2005) 1.14
Long-term survival in HIV positive patients with up to 15 Years of antiretroviral therapy. PLoS One (2012) 1.14
Rates of HIV immune escape and reversion: implications for vaccination. Trends Microbiol (2008) 1.14
NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol (2011) 1.13
Chimeric human papilloma virus-simian/human immunodeficiency virus virus-like-particle vaccines: immunogenicity and protective efficacy in macaques. Virology (2002) 1.12
Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per milliliter. J Clin Microbiol (2008) 1.11
Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS (2012) 1.11
In vivo fitness costs of different Gag CD8 T-cell escape mutant simian-human immunodeficiency viruses for macaques. J Virol (2007) 1.11
Age-associated cross-reactive antibody-dependent cellular cytotoxicity toward 2009 pandemic influenza A virus subtype H1N1. J Infect Dis (2013) 1.10
Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS (2011) 1.08
Risk factors and causes of death in the Australian HIV Observational Database. Sex Health (2006) 1.07
Killing kinetics of simian immunodeficiency virus-specific CD8+ T cells: implications for HIV vaccine strategies. J Immunol (2007) 1.07
Screening and confirmatory testing of MHC class I alleles in pig-tailed macaques. Immunogenetics (2011) 1.05
Quantification of simian immunodeficiency virus cytotoxic T lymphocyte escape mutant viruses. AIDS Res Hum Retroviruses (2008) 1.05
Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen. J Virol (2007) 1.05
Preferential infection of dendritic cells during human immunodeficiency virus type 1 infection of blood leukocytes. J Virol (2006) 1.04
Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine (2005) 1.04
The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr (2009) 1.04
The benefits of sensorimotor knowledge: body-object interaction facilitates semantic processing. Cogn Sci (2008) 1.03
A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice. Mol Ther (2007) 1.03
Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Int AIDS Soc (2012) 1.03
Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global use. Vaccine (2005) 1.02
A protective vaccine delivery system for in vivo T cell stimulation using nanoengineered polymer hydrogel capsules. ACS Nano (2009) 1.02
HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity. J Virol (2012) 1.02
Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther (2005) 1.01
Modeling trends in HIV incidence among homosexual men in Australia 1995-2006. J Acquir Immune Defic Syndr (2004) 1.00
Timing of immune escape linked to success or failure of vaccination. PLoS One (2010) 1.00
CD4+ target cell availability determines the dynamics of immune escape and reversion in vivo. J Virol (2008) 1.00
Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol (2011) 1.00